Biotech Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Asahikawa Medical College
Studies from the United States and Germany describe new findings in cancer treatment research
June 23rd, 2006
Investigators in the United States and Germany have published new cancer treatment data. Study 1: MHC class II T helper epitopes for WT1 tumor antigen may aid vaccine development. According to researchers in Japan and the United States, "The product of Wilms' tumor gene 1 (WT1) is overexpressed in diverse human tumors, including leukemia, lung, and breast cancer, and is often recognized by antibodies in the sera of patients with leukemia. Since WT1 encodes MHC class I-restricted peptides recognized by cytotoxic T lymphocytes (CTL), WT1 has been considered as a promising tumor-associated antigen (TAA) for developing anticancer immunotherapy. In order...
Source: Biotech Law Weekly (2006-06-23)
|
